At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 118 enrolled
Drug / intervention
Apalutamide +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Randomized Study Of Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide For Intermediate-High Risk Prostate Cancer Undergoing Prostatectomy
In Brief
A Phase 2 clinical trial evaluating Apalutamide, Leuprolide, and 2 other interventions for Prostate Cancer. Completed, enrolled 118 participants across 4 sites.
Detailed Summary
This multicenter randomized phase II trial investigates the impact of intense androgen deprivation on radical prostatectomy (RP) pathologic response and radiographic and tissue biomarkers in localized prostate cancer (NCT02903368).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsJanssen Scientific Affairs, LLC
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartOct 2016
Primary CompletionApr 2022
Study CompletionJul 2024
TodayJul 2026
First PostedSep 16, 2016
Enrollment StartOct 19, 2016
Primary CompletionApr 5, 2022
Study CompletionJul 10, 2024
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 9.8 years ago
Interventions
Apalutamidedrug
Leuprolidedrug
Prednisonedrug
Abiraterone Acetatedrug